Fujian Haixi Pharmaceuticals Co., Ltd. (hereinafter referred to as "Haixi Pharma") was established in Fuzhou in March 2012 with the strong support from both the Fujian provincial and Fuzhou municipal governments and relevant authorities. Haixi Pharma is a pharmaceutical enterprise built around the Marketing Authorization Holder (MAH) system, covering the entire industry value chain from R&D, clinical research, and manufacturing to commercialization.

       Over the past course 13 years, Haixi Pharma has taken an extraordinary development path – pursuing a dua strategy of generics and innovative drugs, adhering to the principle of "generics empower innovation, innovation drives the future".

       In generics, the company focuses on the research and development of first-to-market generics, difficult-to-formulate generics, and high-value-generics. By leveraging favorable national pharmaceutical policies—such as the MAH system, generic drugs  consistency evaluation, and the national centralized drug procurement-Haixi Pharma has achieved remarkable results. As of October 2025, 13 drugs have been approved for marketing and sale by the National Medical Products Administration (NMPA).